Catalyst Pharma Revenue, Profits - CPRX Annual Income Statement

Add to My Stocks
$3.07 $0.03 (0.97%) CPRX stock closing price Sep 19, 2018 (Closing)

CPRX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Catalyst Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 impacts the CPRX stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2017 is $- and has decreased from $- year on year as is evident when you compare the latest figures in the latest Catalyst Pharma profit and loss statement with those of the prior corresponding period. Also see Catalyst Pharma assets and Catalyst Pharma free cash flow for a complete valuation of CPRX stock.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Catalyst Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Catalyst Pharma Gross Profit
Research & Development Expense11.37M11.36M11.8M10.11M8.09M2.65M3.38M2.3M5.09M8.71M
Selling General & Admin Expense7.3M7.91M8.59M4.47M2.21M2.56M2.69M2.2M2.17M2.18M
Income Before Depreciation Depletion Amortization-18.67M-19.28M-20.39M-14.59M-10.31M-5.22M-6.08M-4.02M-7.27M-10.89M
Depreciation Depletion Amortization----------
Non Operating Income-1.2M--0.91M-1.84M1.14M-0.3M---
Interest Expense----------
Catalyst Pharma Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-18.41M-18.07M-20.23M-15.5M-12.15M-4.07M-6.39M-4M-7.24M-10.56M
Extraordinary Items & Discontinued Operations----------
Catalyst Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS85.8M82.88M80.86M64.14M45.45M30.03M21.73M18.58M15.07M13.01M
Average Shares used to compute Basic EPS85.8M82.88M80.86M64.14M45.45M30.03M21.73M18.58M15.07M13.01M
Income Before Nonrecurring Items-18.41M-18.96M-20.3M-14.52M-14.05M-5.21M-6.07M-4.01M-7.24M-10.57M
Income from Nonrecurring Items----0.99M1.89M1.13M-0.32M---
Catalyst Pharma Earnings Per Share Basic Net
Catalyst Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.21-0.23-0.25-0.23-0.31-0.18-0.28-0.22-0.48-0.81
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Catalyst Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that CPRX stock has a topline or revenue of $- for 2017 as per this Catalyst Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-18.41M for CPRX stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the CPRX income statement, one can check the Catalyst Pharma historical stock prices to check how the price has moved with time.

Catalyst Pharma Income Statement - Key Financial Ratios